A real-world data (RWD) study published in JAMA Oncology finds that administering immunotherapy to patients with advanced non-small cell lung cancer (NSCLC) is appropriate. The study, which followed 1091 patients at Penn Medicine’s Abramson Cancer Center, found that patients whose cancer hasn’t […]
Molecular Templates’ Multiple Myeloma Trial Partial Hold Lifted
Molecular Templates’ clinical trial for MT-0169, its experimental multiple myeloma therapeutic, is back on, following the US Food and Drug Administration (FDA) lifting a partial hold. The hold was placed on the trial following two adverse events experienced by patients, who both recovered. The move […]
Real World Data Study Finds Comprehensive Genomic Profiling Improves Cancer Outcomees
Real-world data (RWD) to be presented at this year’s upcoming American Society of Clinical Oncology’s Annual Meeting shows that comprehensive genomic profiling (CGP) improves cancer patients’ outcomes. The study, which covered 1,423 advanced cancer patients who received CGP from 2019 to 2021, showed […]
Looking at Real-World Data Supporting Durvalumab in NSCLC
In a new Targeted Oncology Case-Based Roundtable, clinicians discussed new real-world data (RWD) supporting the use of durvalumab in unresectable stage III non-small cell lung cancer (NSCLC). The clinicians discussed their use of the immunotherapy, noting that most of them continued the treatment […]
Yuhan Corp. Releases Real-World Data Supporting Leclaza in Lung Cancer
Researchers at Korea’s National Cancer Center have released new real-world data (RWD) supporting the use of Yuhan Corp’s Leclaza (lazertinib) in the treatment of a subset of non-small cell lung cancer (NSCLC). The study, basefd on data from 103 patients who used Leclaza as a […]
US House Members Call on FDA to Address Chemotherapy Shortages
A bipartisan group of US House representatives is calling on the Food and Drug Administration (FDA) to address ongoing shortages of key chemotherapy drugs. In a letter written by Debbie Dingell (D-MI) and Tim Wahlberg (R-MI), lawmakers highlight the current shortages of cisplatin and carboplatin and […]
Max Foundation and BeiGene to provide Free Brukinsa to 29 LMICs
The Max Foundation, a Seattle-based organization dedicated to health equity, is collaborating with the biotech BioGene to provide Brukinsa to patients with chronic lymphocytic leukemia (CLL) in 29 lower- and middle-income countries (LMICs). The program will last for 3 years and will also provide […]
ImmunityBio’s Marketing Application for Bladder Cancer Medication Shot Down by FDA
ImmunityBio took a loss today after receiving news its marketing application for its bladder cancer drug Anktiva was rejected by the US Food and Drug Administration (FDA). The decision came primarily because of issues with manufacturing facilities. The agency also wants more safety data and […]
Real-World Data Study Examines the Past Decade of Biomarker Testing for Lung Cancer
A real-world data study presented at this year’s ISPOR meeting showed that biomarker testing for early-stage non-small cell lung cancer (NSCLC) increased steadily over the past ten years. Data from over one thousand patients with early-stage NSCLC from 2011 to 2021, finding that 74.1% […]
Real-World Data Study Investigates HER2-Low Vs HER2-Zero Triple-Negative Breast Cancer
A newly published real-world data (RWD) study in Breast Cancer: Targets and Therapy takes a look at the clinical factors and sociodemographics of patients with HER2-low and HER2-zero triple-negative breast cancer at the Brazilian National Cancer Institute. Analysis shows that that there were no […]